Armata Pharmaceuticals, Inc. 8-K

What Happened
Armata Pharmaceuticals, Inc. (ARMP) filed an 8-K on June 16, 2026 reporting results from its June 11, 2026 Annual Meeting of Shareholders. Shareholders elected seven directors (one-year terms through the 2027 annual meeting), approved the non-binding "say-on-pay" advisory vote and a one-year frequency for future say-on-pay votes, and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Directors elected (each for a one-year term; broker non-votes: 1,257,467):
  • Deborah L. Birx, M.D.: 28,349,266 for; 242,970 withheld
  • Daniel B. Gilmer, Ph.D.: 28,543,542 for; 48,694 withheld
  • Jules Haimovitz: 28,350,690 for; 241,546 withheld
  • Odysseas D. Kostas, M.D.: 28,353,918 for; 238,318 withheld
  • Robin C. Kramer: 28,537,772 for; 54,464 withheld
  • Joseph M. Patti, Ph.D.: 28,544,094 for; 48,142 withheld
  • Sarah Schlesinger, M.D.: 28,354,046 for; 238,190 withheld
• Say-on-pay (non‑binding): 28,547,283 for; 27,765 against; 17,188 abstaining; 1,257,467 broker non-votes.
• Advisory vote on frequency: one-year selected — 28,567,809 for one year; 2,400 for two years; 17,113 for three years; 4,914 abstaining; 1,257,467 broker non-votes. The board will hold annual advisory votes on executive compensation.
• Auditor ratification: Ernst & Young LLP ratified as auditor for fiscal 2026 — 29,842,514 for; 6,631 against; 558 abstaining; 0 broker non-votes.

Why It Matters
These results show shareholder support for the current board slate and the company’s executive compensation approach, with a clear preference for annual say-on-pay votes going forward. Ratification of Ernst & Young as auditor confirms continuity in external financial oversight for the 2026 fiscal year. Investors should view this as governance outcomes rather than operational or financial performance disclosures; no financial results or management changes were reported in this filing.